Fair Value Measurements - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net proceeds from sale of businesses	$ 1,491.9	$ 187.8	$ 182.5
Long-term growth rate | Oral care
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Indefinite-lived intangible assets, measurement input (percent)	0.020
Tax rate | Oral care | Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discounted cash flow (percent)	0.165
Tax rate | Oral care | Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discounted cash flow (percent)	0.291
Discount rate | Oral care
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discounted cash flow (percent)	0.0975
Royalty Pharma Contingent Milestone Payments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net sales threshold to trigger milestone payment		351.0
Royalty Pharma contingent payment sales threshold		400.0
Net sales included in calculation for milestone payment				$ 337.5
Royalty Pharma Contingent Milestone Payments | Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty Pharma asset value	$ 0.0	95.3	(95.3)
Change in fair value		$ (95.3)	22.1
Net proceeds from sale of businesses			$ 250.0